These data suggest that kaempferol may be an effective therapeutic candidate to potentiate pancreatic cancer cell sensitivity to Erlotinib via the inhibition of EGFR and PI3K/AKT signaling [93]. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.